Twist Bioscience Corp

Twist Bioscience Corp(TWST)股票分析

$141.380

-10.830 (-7.66%)收盘时

Loading chart…
High
153.110
Open
150.050
VWAP
145.16
Vol
1.38M
Mkt Cap
2.76B
Low
140.990
Amount
200.40M
EV/EBITDA, TTM
-68.46

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.

AI analysis of Twist Bioscience Corp (TWST)

buy

Twist Bioscience Corp is a good buy right now due to its current price of $141.38 being significantly lower than the analyst price target of $115, indicating potential upside. The company also shows a strong gross margin of 52.76% and has experienced a remarkable year-to-date change of +336.49%. However, the main risk is its negative earnings per share (EPS) of -0.56, indicating ongoing losses.

Analyst Ratings (3)

-70.82% downside
Buy
2 Buy
1 Hold
0 Sell
Current: 141.38
最低
39.00
平均
41.25
最高
43.00

Piper Sandler

2026-08-05

目标价

$115

Overweight

Baird

2026-08-04

目标价

$115

Outperform

TD Cowen

2026-08-03

目标价

$115

Buy

Canaccord

2026-07-14

目标价

$120

Buy

Evercore ISI

2026-07-06

目标价

$102

In Line

估值指标

The current forward P/E ratio for Twist Bioscience Corp (TWST) is 0.00, compared to its 5-year average forward P/E of -13.73.

Forward P/E

Overvalued
5Y Average P/E
-13.73
Current P/E
0.00
高估
-6.47
低估
-20.98

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-17.53
Current EV/EBITDA
-68.46
高估
-5.53
低估
-29.54

Forward P/S

Overvalued
5Y Average P/S
8.29
Current P/S
17.80
高估
14.47
低估
2.11

Alphio AI Price Scenarios for TWST

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TWST

$42.17

情景价格

B

Base

Base · 50%TWST

$34.59

情景价格

B

Bear

Bear · 25%TWST

$32.47

情景价格

Whales holding TWST

G

Granahan Investment Management, LLC

+ HoldingTWST

+12.25%

3M Return

E

EdgePoint Investment Group Inc.

+ HoldingTWST

+9.03%

3M Return

P

Peregrine Capital Management, LLC

+ HoldingTWST

+6.74%

3M Return

A

ARK Investment Management LLC

+ HoldingTWST

+4.40%

3M Return

W

William Blair Investment Management, LLC

+ HoldingTWST

+0.41%

3M Return

事件时间线

2026-08-27 (ET)

12:00:00

SoftBank Plans Up to $20B Bond Offering for Refinancing

2026-08-05 (ET)

06:30:00

Deal Size Increased to $300M

2026-08-04 (ET)

08:30:00

Twist Bioscience Grants 44,434 RSUs to 24 New Hires

2026-08-03 (ET)

07:30:00

Company Reports Q3 Revenue of $118.4M, Exceeding Expectations

2026-06-18 (ET)

16:30:00

Twist Bioscience Files Automatic Mixed Securities Shelf

资讯

TWST FAQ — answered by Alphio AI

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Twist Bioscience Corp is a good buy right now due to its current price of $141.38 being significantly lower than the analyst price target of $115, indicating potential upside. The company also shows a strong gross margin of 52.76% and has experienced a remarkable year-to-date change of +336.49%. However, the main risk is its negative earnings per share (EPS) of -0.56, indicating ongoing losses.

3 analysts cover TWST: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 41.25.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始